KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 123 filers reported holding KEROS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,923,671 | -13.5% | 60,341 | +9.0% | 0.05% | -31.4% |
| Q2 2023 | $2,223,601 | +14.5% | 55,341 | +21.7% | 0.07% | +16.7% |
| Q1 2023 | $1,942,167 | -99.8% | 45,484 | +36.5% | 0.06% | +150.0% |
| Q3 2022 | $1,254,000,000 | -20.8% | 33,321 | -41.9% | 0.02% | +4.3% |
| Q2 2022 | $1,584,000,000 | – | 57,321 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |